Trial Outcomes & Findings for Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome (NCT NCT00822679)
NCT ID: NCT00822679
Last Updated: 2016-12-20
Results Overview
Not performed. Zero subjects were randomized. Many potential participants screen-failed.
COMPLETED
PHASE4
5 participants
2 days
2016-12-20
Participant Flow
Potential participants screen failed. There was no subject randomized (n=0).
Participant milestones
| Measure |
1: Eszopiclone
Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
Eszopiclone: Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
|
2: Placebo
Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
Placebo: Subjects are given placebo for 3 consecutive nights
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 2 daysPopulation: Not performed. Zero subjects were randomized. Many potential participants screen-failed.
Not performed. Zero subjects were randomized. Many potential participants screen-failed.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 4 daysOutcome measures
Outcome data not reported
Adverse Events
1: Eszopiclone
2: Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place